Overview
- The study published October 22 reported that the electrocatalytic implant restored normal blood glucose in diabetic mice within about 90 minutes and maintained control with repeated use over six weeks while the animals lost up to 10 percent of body weight.
- The implant uses an inorganic catalyst—graphite felt studded with gold nanoclusters and platinum—that is powered wirelessly at 13.56 MHz and linked to a continuous glucose monitor to turn conversion on only when glucose is high.
- Laboratory tests showed the catalyst converted glucose in a five‑litre reservoir approximating human blood volume and the device operated without signs of tissue damage in the short six‑week animal study.
- Researchers emphasize the work is preclinical and the team is pursuing miniaturization and device development toward medical‑device status before any human testing can begin.
- Clinicians and authors warn key unanswered risks include effects of sustained gluconate clearance on kidney function, long‑term catalyst durability, biocompatibility, and the challenge of scaling glucose removal to the much larger human circulation.